208 related articles for article (PubMed ID: 18758209)
1. Eicosapentaenoic acid has a preventive effect on the recurrence of nephrolithiasis.
Yasui T; Suzuki S; Itoh Y; Tozawa K; Tokudome S; Kohri K
Urol Int; 2008; 81(2):135-8. PubMed ID: 18758209
[TBL] [Abstract][Full Text] [Related]
2. The protective role of eicosapentaenoic acid [EPA] in the pathogenesis of nephrolithiasis.
Buck AC; Davies RL; Harrison T
J Urol; 1991 Jul; 146(1):188-94. PubMed ID: 2056589
[TBL] [Abstract][Full Text] [Related]
3. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients.
Ekeruo WO; Tan YH; Young MD; Dahm P; Maloney ME; Mathias BJ; Albala DM; Preminger GM
J Urol; 2004 Jul; 172(1):159-63. PubMed ID: 15201761
[TBL] [Abstract][Full Text] [Related]
4. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention.
Jungers P; Joly D; Barbey F; Choukroun G; Daudon M
Am J Kidney Dis; 2004 Nov; 44(5):799-805. PubMed ID: 15492945
[TBL] [Abstract][Full Text] [Related]
5. Effects of eicosapentaenoic acid on urinary calcium excretion in calcium stone formers.
Yasui T; Tanaka H; Fujita K; Iguchi M; Kohri K
Eur Urol; 2001 May; 39(5):580-5. PubMed ID: 11464041
[TBL] [Abstract][Full Text] [Related]
6. Effect of acute acid loading on acid-base and calcium metabolism.
Osther PJ
Scand J Urol Nephrol; 2006; 40(1):35-44. PubMed ID: 16452054
[TBL] [Abstract][Full Text] [Related]
7. Dietary calcium, dietary protein, and kidney stone formation.
Curhan GC
Miner Electrolyte Metab; 1997; 23(3-6):261-4. PubMed ID: 9387129
[TBL] [Abstract][Full Text] [Related]
8. Do thiazides prevent recurrent idiopathic renal calcium oxalate stones?
Wolf H; Brocks P; Dahl C
Proc Eur Dial Transplant Assoc; 1983; 20():477-80. PubMed ID: 6361755
[TBL] [Abstract][Full Text] [Related]
9. The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD.
Higashihara E; Nutahara K; Horie S; Muto S; Hosoya T; Hanaoka K; Tuchiya K; Kamura K; Takaichi K; Ubara Y; Itomura M; Hamazaki T
Nephrol Dial Transplant; 2008 Sep; 23(9):2847-52. PubMed ID: 18372389
[TBL] [Abstract][Full Text] [Related]
10. Outcome of metabolic evaluation and medical treatment for calcium nephrolithiasis in a private urological practice.
Mardis HK; Parks JH; Muller G; Ganzel K; Coe FL
J Urol; 2004 Jan; 171(1):85-8. PubMed ID: 14665850
[TBL] [Abstract][Full Text] [Related]
11. [Metabolic evaluation of recurrent idiopathic calcium stone disease in Portugal].
Serra A; Domingos F; Salgueiro C; Prata MM
Acta Med Port; 2004; 17(1):27-34. PubMed ID: 15636725
[TBL] [Abstract][Full Text] [Related]
12. Nephrolithiasis: treatment, causes, and prevention.
Hall PM
Cleve Clin J Med; 2009 Oct; 76(10):583-91. PubMed ID: 19797458
[TBL] [Abstract][Full Text] [Related]
13. Diet to reduce mild hyperoxaluria in patients with idiopathic calcium oxalate stone formation: a pilot study.
Nouvenne A; Meschi T; Guerra A; Allegri F; Prati B; Fiaccadori E; Maggiore U; Borghi L
Urology; 2009 Apr; 73(4):725-30, 730.e1. PubMed ID: 19193409
[TBL] [Abstract][Full Text] [Related]
14. [Effects of eicosapentaenoic acid in patients with bronchial asthma].
Hashimoto N; Majima T; Ichimura K; Iwata T; Suguro H; Horie T
Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Jun; 35(6):634-40. PubMed ID: 9294297
[TBL] [Abstract][Full Text] [Related]
15. [Effect of thiazide therapy in the prophylaxis of calcium lithiasis].
Fernández Rodríguez A; Arrabal Martín M; García Ruiz MJ; De Haro Muñoz T; Zuluaga Gómez A
Arch Esp Urol; 2001 Nov; 54(9):1047-54. PubMed ID: 11789362
[TBL] [Abstract][Full Text] [Related]
16. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
[TBL] [Abstract][Full Text] [Related]
17. Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation.
Robinson MR; Leitao VA; Haleblian GE; Scales CD; Chandrashekar A; Pierre SA; Preminger GM
J Urol; 2009 Mar; 181(3):1145-50. PubMed ID: 19152932
[TBL] [Abstract][Full Text] [Related]
18. [A nephrologist's tasks in nephrolithiasis].
Marangella M
G Ital Nefrol; 2005; 22(1):16-27. PubMed ID: 15786374
[TBL] [Abstract][Full Text] [Related]
19. [Optimal dosage of chlorthalidone in the prevention of the recurrence of nephrolithiasis is 25 mg per day].
Jaeger P; Portmann L; Jacquet AF; Bugnon JM; Burckhardt P
Schweiz Med Wochenschr; 1986 Mar; 116(10):305-8. PubMed ID: 3961448
[TBL] [Abstract][Full Text] [Related]
20. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate.
Sterrett SP; Penniston KL; Wolf JS; Nakada SY
Urology; 2008 Aug; 72(2):278-81. PubMed ID: 18533229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
